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Melatonin is an ancient molecule which was first identified in the 
late 1950s [1]. It exists in almost every organism starting from the 
primitive ones as prokaryotes to the very complex organisms as the 
humans. Melatonin is known as a circadian rhythm regulator [2]. This 
indoleamide is a neurohormone considered classically to be secreted by 
the pineal gland, nonetheless, it is currently known to be synthesized 
in other organs and tissues such as the retina and cerebellum [3,4], 
iris, ciliary body [5], crystalline lens [6,7], Harderian gland [8] and the 
lacrimal gland [9], spleen, heart, skeletal muscle, liver, stomach, gut, 
placenta, testes, ovaries, cerebral cortex and striatum [10].
Melatonin levels in the body are variable giving the time of the 
day, it increases at night and when light enters the eye and reach the 
retina, melatonin is suppressed [11], such photoreception being due to 
specific ganglion cells in the retina containing the pigment melanopsin 
[12]. This neurohormone is of great importance in the eye, apart from 
the retina it has numerous functions, such as working as an antioxidant 
protecting ocular structures against free radicals. For instance, melatonin 
intraperitoneal injection on rats instantly following an oxidative stress 
has shown to protect the lens against cataract [13]. Melatonin is inversely 
related to intraocular pressure since IOP decreases at night while 
melatonin increases [14]. It also has been proved to reduce intraocular 
pressure (IOP) by decreasing the rate of aqueous humour secretion by 
the non-pigmented ciliary epithelium, resulting in a modulation of IOP 
[15]. More importantly, melatonin is important for the cornea. Studies 
showed that melatonin accelerate corneal wound healing, and it has 
been possible to demonstrate that the effect of melatonin is to increase 
the rate of cell migration rather than mitosis [16]. Besides, melatonin 
has the ability to potentiate the effect of diadenosine tetraphosphate, a 
tear secretion inducer, being suitable to treat one of the most prevalent 
ocular conditions: Dry eye [17].
Treating ocular conditions have many challenges due to poor drug 
delivery because of effective multiple barriers to drug entry, comprising 
nasolacrimal drainage, epithelial drug transport barriers and clearance 
from the vasculature in the conjunctiva [18]. While topical ocular 
bioavailability is extraordinary poor, in the order of 5% or less, sustained 
delivery systems for diseases of the posterior segment such as various 
vitreoretinal disorders through intraocular delivery systems are used 
via implantable devices or injections [19]. However, independently of 
the fact that intraocular drug delivery systems are invasive, up to date, 
long-term drug delivery for diseases of the anterior segment of the eye 
does not exist.
There are several ways for drugs to reach the ocular system, for 
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instance, melatonin orally administered at a concentration of 10 mg 
to patients before performing cataract surgery have shown to lower 
intraocular pressure, consequently, they had better operating condition 
[20]. Melatonin was also investigated for the treatment of uveitis in 
hamsters, experiments were done by injecting 5 mg of melatonin before 
the induction of uveitis, and results suggested that melatonin prevents 
the clinical and biochemical consequences of this disorder [21]. 
Among several factors leading to poor bioavailability of drug 
administered topically, the cornea is the primary barrier of the anterior 
segment due to lipophilicity and tight junctions which restrain the 
entrance of pharmacological substances [22]. In this sense, experiments 
have demonstrated that when melatonin or any of its analogues is 
topically applied, the amount that appears within the eye was between 
3 and 4 orders of magnitude lower than the instilled amount [23]. This 
relevant fact is suggesting that it is necessary to improve the delivery 
ways to permit better results with less amount of melatonin. 
There are three main ideas that can be highlighted: One can be to 
facilitate the entrance through the cornea by modifying the barrier effect. 
Second, to permit melatonin to remain longer on the ocular surface to 
allow a slow but a sustained entrance of this substance. Third to induce 
the intraocular synthesis of melatonin by modulating light wavelength.
Concerning the first idea, an interesting study showed that the 
molecule diadenosine tetraphosphate (Ap4A), has the ability to make 
transiently disappear the corneal tight junctions permitting efficient 
drug delivery to the eye. A study showed that 5-MCA-NAT, a melatonin 
analog, had more hypotensive effect when instilled topically on New 
Zealand white rabbits when diadenosine tetraphosphate was applied 
two hours before the melatonin analogue. Indeed, when 5-MCA-
NAT was topically applied after using diadenosine tetraphosphate, the 
amount of this melatonin analogue found within the eye was 3-fold the 
one measured when it was instilled alone [24]. This is indicating that 
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the transient elimination of the corneal tight junctions is an effective 
mechanism to permit the entrance of molecules into the eye [25].
The second idea consists of permitting melatonin to remain longer 
on the ocular surface. A possible alternative for a long-term drug 
delivery is the use of contact lenses, in such a way, ocular bioavailability 
will be improved considering reduced tear mixing between the lens 
and the cornea besides the extended drug release [26]. The traditional 
method is to soak the lens in drug solution in order for the drug to be 
absorbed into the polymeric lenses, this way permits limited and slow 
release of the drugs into the post-lens lacrimal fluid [18,27]. Melatonin 
and analogues can be soaked in contact lenses overnight and the lenses 
can be fitted to obtain a sustained release of these substances. In this 
way, when melatonin is topically instilled it lasted no more than 2 min 
on the ocular surface as happens with all compounds applied in this way 
[18]. When melatonin and analogues are released from contact lenses 
the maximal release occurs 2 hours after the lens fitting, their presence 
being measurable for more than 300 min, as it happens with other 
naturally occurring substances [27]. This slow but sustained release of 
melatonin will permit the entry of this substance and therefore a more 
robust intraocular effect. 
The third idea is based on modifying the light that enters the eye in 
order to induce the natural production of melatonin in the lens, instead 
of applying it exogenously. Recently, it has been possible to describe 
the presence of melanopsin in the lens epithelium [28]. This pigment 
abolishes the synthesis of melatonin when the lens is illuminated with 
blue light (including the blue component of white light). Therefore, it 
is possible to induce the synthesis of melatonin by reducing the blue 
component of white light (460-490 nm wavelength) by means of filters. 
Interestingly, white light permits a discrete synthesis of melatonin 
in lens epithelial cells (about 20 pmol/106 cells), but the blockade of 
blue light permits levels which are 3-fold higher (60 pmol/106 cells) 
[28]. This regulation of the local synthesis of melatonin by filtering 
light, could be an interesting approach to induce melatonin synthesis 
intraocularly and to help in processes such as the reduction of IOP and 
cataract prevention. 
In summary, melatonin has proven effective for several ocular 
disorders and it could be interesting to investigate the best possible way 
for its delivery giving the challenges ophthalmologists are facing due to 
limited non-invasive drug delivery systems to the eye.
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